| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.004 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.005 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.005 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.006 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.092 | 0.006 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.089 | 0.006 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.093 | 0.006 |